Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.22 - $0.66 $41,110 - $123,330
186,865 Added 6.71%
2,970,346 $1.16 Million
Q3 2023

Nov 13, 2023

BUY
$0.2 - $1.78 $12,537 - $111,581
62,686 Added 2.3%
2,783,481 $612,000
Q2 2023

Aug 11, 2023

BUY
$1.02 - $1.89 $186,782 - $346,096
183,120 Added 7.22%
2,720,795 $4.73 Million
Q1 2023

May 15, 2023

BUY
$1.0 - $1.35 $475,477 - $641,893
475,477 Added 23.06%
2,537,675 $2.77 Million
Q4 2022

Feb 13, 2023

SELL
$0.87 - $1.33 $1,305 - $1,996
-1,501 Reduced 0.07%
2,062,198 $2.23 Million
Q3 2022

Nov 14, 2022

BUY
$1.02 - $1.26 $6,007 - $7,421
5,890 Added 0.29%
2,063,699 $2.52 Million
Q2 2022

Aug 12, 2022

BUY
$0.91 - $2.01 $175,815 - $388,340
193,204 Added 10.36%
2,057,809 $2.1 Million
Q1 2022

May 13, 2022

BUY
$1.22 - $2.03 $403,552 - $671,485
330,781 Added 21.57%
1,864,605 $3.32 Million
Q4 2021

Feb 11, 2022

SELL
$1.27 - $2.23 $23,639 - $41,509
-18,614 Reduced 1.2%
1,533,824 $2.09 Million
Q3 2021

Nov 12, 2021

BUY
$2.12 - $2.76 $77,064 - $100,328
36,351 Added 2.4%
1,552,438 $3.37 Million
Q2 2021

Aug 13, 2021

BUY
$1.78 - $2.76 $1.38 Million - $2.14 Million
774,405 Added 104.41%
1,516,087 $3.78 Million
Q1 2021

May 12, 2021

BUY
$0.94 - $3.31 $444,668 - $1.57 Million
473,052 Added 176.1%
741,682 $1.67 Million
Q4 2020

Feb 12, 2021

BUY
$0.7 - $1.58 $43,785 - $98,830
62,551 Added 30.35%
268,630 $349,000
Q3 2020

Nov 13, 2020

BUY
$0.61 - $1.6 $52,818 - $138,540
86,588 Added 72.46%
206,079 $148,000
Q2 2020

Aug 13, 2020

BUY
$0.56 - $1.41 $29,262 - $73,678
52,254 Added 77.72%
119,491 $154,000
Q3 2019

Nov 12, 2019

BUY
$1.32 - $2.63 $45,879 - $91,410
34,757 Added 107.01%
67,237 $100,000
Q2 2019

Aug 14, 2019

BUY
$0.91 - $7.68 $29,556 - $249,446
32,480 New
32,480 $67,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.26B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.